A systematic review of model-based economic evaluations of treatments for venous leg ulcers by Layer, Ashley et al.
1 
 
TITLE PAGE 
Title: A systematic review of model-based economic evaluations of treatments for venous leg 
ulcers 
Short Running Title: Model-based economic evaluations for venous leg ulcers 
Manuscript word count: 4254 
Table count: 1 
Figure count: 1 
Supplementary material: 2 
Authors: 
Ashley Layer1 
*E McManus2 
N J Levell3 
Affiliations: 
1 Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ 
2 Health Economics Group, Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ.  
3 Dermatology Department, Norfolk and Norwich University Hospitals NHS Foundation Trust, Colney 
Lane, Norwich, NR4 7UY 
*Corresponding Author: 
Emma McManus (OCRID: 0000-0002-3442-8721) 
Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ 
Emma.mcmanus@uea.ac.uk 
01603 59 2443 
 
Funding Source: 
No funding was received for the writing of this manuscript. 
Competing interests: 
The authors, AL, EM and NJL, declare that they have no competing interests.  
 
Abstract 
Objective The aim of this review was to identify, and assess the quality of, published model-based 
economic evaluations relating to treatments for patients with venous leg ulcers to help inform future 
decision-analytic models in this clinical area. 
Methods A systematic literature search was performed on six electronic databases, from database 
inception until 21st May 2018. Search results were screened against predefined criteria by two 
independent reviewers. Data was then extracted from the included studies using a standardised form, 
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whilst the decision-analytic model specific, Philips Checklist was used to assess quality and to inform 
model critique. 
Results 23 models were identified, 12 studies used a Markov modelling approach, five used decision 
trees and six studies did not detail the model type. Studies were predominantly from the NHS/payer 
perspective, with only 2/23 taking a societal perspective. Interventions were wide ranging, but 
dressing technologies (11/23) were most common. The intervention studied was found to be dominant 
in 22/23 studies. The reporting quality of papers was mostly low, with evidence behind model 
structures, time horizons and data selection consistently underreported across the included papers. 
Conclusions This review has identified a sizeable literature of model-based economic evaluations, 
evaluating treatments for venous leg ulcers. However, the methods used to conduct such studies 
were generally poorly reported. In particular, the reporting of evidence surrounding the model 
structure, justification of the time horizon used and the rationale for selecting data inputs should be 
focused on in any future models developed.  
Keywords: Systematic review, venous leg ulcers, decision-analytic model, economic evaluation 
Key points for decision makers: 
 23 models evaluating the cost effectiveness of treatments for venous leg ulcers were found 
within this systematic review. 
 The most common modelling approach was a Markov model, with studies predominantly 
taking an NHS/payer perspective and evaluating wound dressing technologies. 
 The reporting quality of models was appraised using the Philips Checklist. This found that 
most studies did not adequately report all aspects of the model used. Particularly, limited 
information was given surrounding the modelling techniques and structure.  
 
1 Introduction 
Venous leg ulcers (VLU) are long-lasting wounds of the lower leg. They are usually formed after an 
injury, with slow healing due to increased blood pressure in the leg veins [1]. Typically ulcers take 
three to four months to heal with appropriate treatment [2]. VLUs often cause pain, malodour and fluid 
leakage [3]. These symptoms affect mobility, sleep and daily living, impairing quality of life [3].  
VLUs affect 2% of over 80s in the UK and account for 60-85% of all leg ulcers [4]. The incidence and 
prevalence are increasing due to ageing populations and the global trend of obesity [5-7]. With their 
high prevalence and prolonged healing time, VLUs were estimated to cost the UK NHS £921 million in 
the price year 2012/13 [8]. 
Treatment for VLUs involves wound care and sustained graduated compression therapy [4], with most 
of the direct costs of treatment attributable to community nurse visits [9]. There are also newly 
emerging advanced treatment modalities for VLUs. These include bioengineered tissue, electric 
stimulation and a wide variety of dressing variations [10]. A recent Cochrane systematic review 
concluded that there is low-certainty evidence for the clinical efficacy of novel dressings and topical 
agents in VLUs [4, 7, 11]. 
However, due to limited health care budgets and the increasing demand for services, it is now no 
longer enough to demonstrate a treatment as clinically effective, it also must be shown to be value for 
money, or cost-effective [12]. Economic evaluations seek to address this question, comparing 
alternative courses of actions in terms of their costs and consequences, to determine which 
represents the most effective use of resources. Often such evaluations are conducted alongside 
clinical trials, however the time horizons of such trials are usually dictated by the primary clinical 
outcome and therefore may end before all of the costs and outcomes, which are of economic interest, 
have been fully observed. Instead, decision-analytic models can be used [13], such models do not 
have a restriction on the time horizon over which they can model, can take into account multiple 
treatment options, use data from multiple sources and perhaps most importantly, can assess the 
uncertainty surrounding a decision. 
There are several studies published using decision-analytic models to conduct economic evaluations 
of treatments for VLUs. However, there have been no reviews of these studies to collate and critically 
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appraise the methods used. Given this and the likelihood that newly emerging treatment modalities 
will need to be evaluated in the future, this review aimed to identify, evaluate and critically appraise, 
all published model-based economic evaluations relating to the treatment of VLUs. In doing so, it is 
hoped that it will facilitate researchers developing future VLU models in the common methodologies 
used as well as areas that may require particular attention. 
2 Methods 
This systematic review was conducted and reported according to PRISMA (Preferred Reporting Items 
for Systematic reviews and Meta-Analyses) guidelines [14]. The review has been registered on 
PROSPERO, the international prospective register of systematic reviews, under the registration 
number CRD42018102852. 
2.1 Eligibility Criteria 
Studies were considered eligible if they described a full economic evaluation using a decision analytic 
model to evaluate any intervention for VLUs. A decision-analytic model was considered to be one 
which used mathematical techniques to define a series of possible consequences depending on 
alternative options [13, 15]. Where a study considered other wounds as well as VLU, it was made a 
condition that the results for the VLU population be presented separately. Patients of all ages, 
geographical location and sex, were considered eligible for inclusion. Notably, studies detailing 
preventions for venous leg ulcers were excluded. In addition to the above constraints, only articles 
available in full text in English were considered due to resource limitations. All abstracts and reviews 
were excluded. 
  
2.2 Search Strategy 
A systematic search of electronic databases was conducted, from database inception until 21st May 
2018, when the search was conducted. The search was applied to MEDLINE, Embase, Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), Econlit, Web of Science and NHS Economic 
Evaluation Database (NHS EED). Database selection was structured from research and 
recommendations from Thielen et al [16]. The search strategy itself was formed with the help of a 
biomedical information specialist, and was specialised to detect economic evaluations through the 
use of published search filters [17-19]. The full search strategy is available in the Electronic 
Supplementary Material (Appendix 1), with search terms including “venous ulcer*”, “varicose ulcer*” 
and “cost*”.  
2.3 Study Selection 
After duplicates were removed, study selection occurred in two stages; and was performed 
independently by two reviewers (AL and EM). Initially, titles and abstracts were screened, with full 
texts then obtained for studies that appeared to meet the inclusion criteria. These full texts were then 
again screened against the inclusion criteria to assess eligibility for inclusion in the review, with 
reasons for exclusion noted down. All conflicts were resolved by discussion between the two 
reviewers. All eligible studies had their references screened, to ensure that no papers had been 
missed from the search strategy. 
2.4 Data Extraction 
Data extraction was performed independently by two reviewers (AL and EM) using a standardised 
form. This form was piloted on an initial study, to allow it to be refined. Data collected pertained to the 
study characteristics, details of the decision-analytic model and the results and conclusions of the 
study. Any disagreements were resolved by discussion, with a template of the data extraction form 
found in the Electronic Supplementary Material (Appendix 2) and the populated data extraction form 
also included as an Electronic Supplementary File. 
2.5 Quality Assessment 
Quality assessment was carried out using the Philips Checklist [20], an extensive checklist specifically 
designed for the assessment of modelling studies and recommended by both the National Institute for 
Health and Clinical Excellence (NICE) and the Cochrane Collaboration [21-23]. The checklist was 
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completed independently by two reviewers (AL and EM), with any disagreements regarding answers 
resolved by discussion. Possible responses for the items on the checklist were ‘yes’, ‘no’, ‘not 
applicable’ (for items that were not relevant to the study) and ‘partial’ (for items which had multiple 
elements, of which only some were satisfactorily fulfilled by the study).  
3. Results 
The literature search returned a total of 2,515 studies. After removing duplicate papers and initial 
screening of titles and abstracts, 130 full-texts were retrieved and assessed for eligibility. 23 studies 
were included within the review. This study selection process is summarised in Figure 1. 
3.1. Study Characteristics 
Table 1 summarises the included studies.  
The most common intervention type across the studies were dressings for VLUs, the subject of 11 
studies (48%) [24-34]. There were also four studies each focusing on compression bandaging [35-38] 
and extracellular matrices [39-42]. The other interventions included by papers in the review were 
electric stimulation therapies [43, 44], barrier creams [45] and pentoxifylline oral medication [46]. 
Comparators varied greatly across studies depending on intervention type, with ten studies using 
more than one comparator [24, 25, 29, 32, 33, 36-38, 41, 45]. Eight studies used ‘standard care’ as a 
comparator, with all of these papers giving a definition of what ‘standard care’ involved at some point 
in the text [27, 34, 39, 41, 43-46]. 
The publication year of these studies ranged from 1999 to 2018. Ten of the studies (43%) were 
published in the Journal of Wound Care [24-27, 35-37, 39, 43, 45], with no other journal responsible 
for more than one paper. There were 11 cost effectiveness analyses (CEAs) [26, 28-33, 35, 40-42] 
and three cost utility analyses (CUAs) [25, 36, 38], with the remaining nine studies a combination of 
both CEA and CUA [24, 27, 34, 37, 39, 43-46]. For the CEAs, the most common clinical outcome 
related to percentage of patients healed (12 outcomes) [26, 27, 30, 32, 33, 37, 39, 41-45], with time 
taken for the ulcer to heal used as an outcome in ten studies [24, 25, 29, 31, 34-36, 41, 42, 46], and 
reduction in wound area size used twice [28, 29]. It should be noted that whilst these outcome 
measures may be clinically meaningful within VLUs, they do not have a willingness to pay threshold 
attached to them (such as with the quality adjusted life year), and that they do not facilitate 
comparison to other economic evaluations conducted within other disease areas. 
For the CUAs, quality-adjusted life years (QALYs) were the only measurement of utility used. Nine 
decision-analytic models sourced utilities for their QALY measurements from the 2007 study by Clegg 
and Guest [25, 27, 34, 36, 37, 39, 43-45]. This paper used standard gamble methodology on a 
sample of 200 participants, including both the general population and VLU patients, to allow for 
utilities to be assigned to different VLU states [44]. The remaining three QALY measurements 
obtained utility values from randomised controlled trials which used the EuroQol 5D and/or Short 
Form 6D questionnaires [24, 38, 46].  
The payer perspective was taken in 18 papers [24-28, 30, 31, 34, 36-39, 41-46], with only two studies 
(9%) stating that they had taken a societal perspective [29, 40]. Three papers did not state the 
perspective used [32, 33, 35]. 
Markov models were the most common decision-analytical approach, being used in 12 (52%) studies 
[24, 28, 29, 34, 35, 38, 39, 41-44, 46]. The most common time cycle length used for these models 
was one week with a one year time horizon, found in five studies [24, 34, 35, 41, 46]. Other time 
horizons varied greatly, from 14 days [28] to 12 years [38]. Decision-tree models were used in five 
studies [27, 30, 31, 36, 45], and the remaining six studies did not explicitly state their model type [25, 
26, 32, 33, 37, 40]. For these six studies, no figure was included to describe the model structure, 
making it difficult to appreciate the type of model used. Transition probabilities for models were 
described in 12 of the 23 studies (52%), with two studies stating that probabilities could be “obtained 
 
FIGURE 1 HERE 
Fig.1 PRISMA Diagram of Study Selection Process 
5 
 
directly from the corresponding author” [39, 43]. Nine studies did not state any of the transition 
probabilities used in their models [25, 26, 31-33, 35-37, 45]. 
Of the 23 studies included in the review, 22 reported that the intervention was dominant. The one 
study without a dominant intervention, evaluating a skin substitute (Apligraf), had an incremental cost 
effectiveness ratio (ICER) of $14 per ulcer day avoided [40]. Almost all studies (91%) in the review 
were funded by medical companies, other than the studies by Ashby et al (HTA programme fund) [38] 
and by Iglesias and Claxton (funded by the University of York) [46]. 
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Table 1: Summary of characteristics of included studies 
Study 
EE 
Type 
Intervention Comparator 
Country, 
Perspective 
Currency, 
Price Year 
Model Type 
(cycle length, 
time horizon) 
Model States / 
Tree Summary 
Outcome 
Measures 
Sensitivity 
Analysis 
Result 
Markov Models 
Carr et al. 
1999 [35] 
CEA 
Four-layer 
bandaging 
system 
(Profore) 
Charing Cross 
System of four-
layer bandaging 
UK, Not 
stated 
GBP (£) 
1997/98 
Markov Model 
(1 week, 1 year) 
Healed and 
unhealed 
Median time 
to heal 
Univariate 
Deterministic 
Intervention 
Dominant 
Schonfeld 
et al. 
2000 [42] 
CEA 
Skin 
Substitute 
(Apligraf) 
Zinc-
impregnated 
gauze (Unna's 
boot) 
USA, 
Commercial 
health plan 
USD ($) 
Markov Model 
(1 month, 1 
year) 
Unhealed, 
healed, 
recurrence, no 
therapy 
Number of 
months 
during the 
year in a 
healed ulcer 
state, 
% of patients 
with healed 
ulcers 
Univariate 
Deterministic 
Intervention 
Dominant 
Scanlon 
et al. 
2005 [29] 
CEA 
Silver-
releasing 
dressing 
(Contreet 
Foam) 
Aquacel Ag, 
Actisorb Plus, 
Iodoflex 
UK, Societal 
GBP (£) 
2003/04 
Markov Model 
(1 week, 26 
weeks) 
Healed, non-
healed 
Percentage 
reduction in 
wound area, 
Number of 
healed 
wounds 
Univariate 
Deterministic 
Intervention 
Dominant 
Iglesias et 
al. 2006 
[46] 
CEA 
+ 
CUA 
Oral 
Pentoxifylline 
Placebo with 
Standard Care 
(Compression 
therapy and 
wound 
dressings) 
UK, NHS 
GBP (£) 
2004 
Markov Model 
(1 week, 1 year) 
Healed, 
unhealed, death 
Ulcer free 
weeks, 
QALYs 
Univariate 
Deterministic 
Intervention 
Dominant 
Clegg et 
al. 2007 
[44] 
CEA 
+ 
CUA 
Bio-electric 
stimulation 
therapy 
(Posifect) 
Standard Care 
(Compression 
therapy and 
wound 
dressings) 
UK, NHS 
GBP (£) 
2005/06 
Markov Model 
(1 week, 16 
weeks) 
Healed, 
improved, 
unchanged, 
worsened, dead 
% of healed 
patients at 16 
weeks, 
QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
Guest et 
al. 2009 
[39] 
CEA 
+ 
CUA 
Amelogenin 
Standard Care 
(Compression 
therapy and 
wound 
dressings) 
UK, NHS 
GBP (£) 
2006/07 
Markov Model 
(1 month, 1 
year) 
Unchanged 
worsened, 
improved, 
healed, 
recurrence, 
dead 
% of healed 
patients, 
QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
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Table 1: Summary of characteristics of included studies 
Study 
EE 
Type 
Intervention Comparator 
Country, 
Perspective 
Currency, 
Price Year 
Model Type 
(cycle length, 
time horizon) 
Model States / 
Tree Summary 
Outcome 
Measures 
Sensitivity 
Analysis 
Result 
Taylor et 
al. 2011 
[43] 
CEA 
+ 
CUA 
Electric 
stimulation 
(Accel-Heal) 
Standard Care 
(Compression 
therapy and 
wound 
dressings) 
UK, NHS 
GBP (£) 
2008/09 
Markov Model 
(1 month, 5 
months) 
Unchanged, 
worsened, 
improved, 
healed, 
recurrence 
Probability of 
healing, 
QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
Carter et 
al. 2014 
[41] 
CEA 
Extracellular 
Matrix 
(OASIS) 
Human Skin 
Equivalent, 
Living Skin 
Equivalent, 
Standard Care 
(Compression 
therapy and 
wound 
dressings) 
USA, Payer 
USD ($) 
2012 
Markov Model 
(1 week, 1 year) 
Unhealed, 
healed, death 
Healed 
Wound 
Weeks, 
Expected 
Wound 
Closure Rate 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
Ashby et 
al. 2014 
[38] 
CUA 
Two-layer 
bandage 
Two-layer 
hosiery, Four-
layer bandage, 
Short-stretch 
bandage, Paste 
bandage 
UK, NHS 
GBP (£) 
2011 
Markov Model 
(1 month, 12 
years) 
Unhealed, 
healed, death 
QALYs Probabilistic 
Intervention 
Dominant 
Kaspar et 
al. 2015 
[28] 
CEA 
Polyacrylate-
based 
hydrogel 
(HydroClean) 
Amorphous 
hydrogel 
Germany, 
Payer 
Euros (€) 
Not stated 
Markov Model 
(1 day, 14 days) 
Wound bed 
covered with 
≤50% 
granulation 
tissue, wound 
bed covered 
with >50% 
granulation 
tissue 
Mean days 
with >50% 
granulation 
tissue 
None 
Intervention 
Dominant 
Nherera 
et al. 
2016 [34] 
CEA 
+ 
CUA 
Iodine 
dressing 
(Cadexomer 
iodine) 
Standard Care 
(Compression 
bandaging with 
debridement) 
USA, Payer 
USD ($) 
2014 
Markov Model 
(1 week, 1 year) 
Healed, 
unhealed, 
infected, dead 
Ulcer free 
weeks, 
QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
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Table 1: Summary of characteristics of included studies 
Study 
EE 
Type 
Intervention Comparator 
Country, 
Perspective 
Currency, 
Price Year 
Model Type 
(cycle length, 
time horizon) 
Model States / 
Tree Summary 
Outcome 
Measures 
Sensitivity 
Analysis 
Result 
Walzer et 
al. 2018 
[24] 
CEA 
+ 
CUA 
Hydration 
Response 
Technology 
Dressing 
(Cutimed 
Sorbion 
Sachet S) 
Four 
superabsorbant 
dressings 
(Zetuvit Plus, 
KerraMax Care, 
Eclypse, 
DryMax extra) 
UK, NHS 
GBP (£) 
Not stated 
Markov Model 
(1 week, 1 year) 
Healed, 
improving, 
unchanged, 
deteriorating, 
infected or 
complications 
Time taken 
to heal 
wound, 
QALY 
Univariate 
Deterministic 
Intervention 
Dominant 
Decision Tree Models 
Guest et 
al. 2005 
[30] 
CEA 
Carboxymeth
ylcellulose 
dressing 
(Aquacel 
hydrofiber) 
Gauze Dressing 
Germany 
and USA, 
Payer 
Euros (€) 
and USD 
($) 
2002/03 
Decision Tree 
Model 
Healed or 
unhealed 
Ulcer 
successfully 
healed at 18 
weeks 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
Guest et 
al. 2012 
[45] 
CEA 
+ 
CUA 
Cavilon No 
Sting Barrier 
Film 
Cavilon Durable 
Barrier Cream, 
Standard Care 
UK, NHS 
GBP (£) 
2009/10 
Decision Tree 
Model 
Not Detailed 
% of healed 
patients at 6 
months 
QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
Jemec et 
al. 2014 
[31] 
CEA 
Silver 
dressing 
(Biatain Ag) 
Non-Silver 
dressings 
UK, NHS 
GBP (£) 
2012/13 
Decision Tree 
Model 
Healed vs 
healing vs no 
improvement + 
specialist care 
Time to 
healed 
wound 
Univariate 
Deterministic 
Intervention 
Dominant 
Guest et 
al. 2015 
[36] 
CUA 
Two-layer 
cohesive 
compression 
bandage 
(Coban 2) 
Other 
compression 
systems (Ktwo, 
Profore) 
UK, NHS 
GBP (£) 
2012/13 
Decision Tree 
Model 
Not Detailed QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
Guest et 
al. 2018 
[27] 
CEA 
+ 
CUA 
Collagen-
containing 
dressing 
Standard Care 
(Compression 
therapy and 
wound 
dressings) 
UK, NHS 
GBP (£) 
2015/16 
Decision Tree 
Model 
See fig 1 
Probability of 
healing 
QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
Model Not Detailed 
Harding 
et al. 
2000 [32] 
CEA 
Hydrocolloid 
Dressing 
(Granuflex) 
Apligraf, Saline 
Gauze 
UK, Not 
Stated 
GBP (£) 
Not stated 
Not Detailed - 
"Cost-
Effectiveness 
Model" 
Not Detailed 
% healed in 
12 weeks 
None 
Intervention 
Dominant 
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Table 1: Summary of characteristics of included studies 
Study 
EE 
Type 
Intervention Comparator 
Country, 
Perspective 
Currency, 
Price Year 
Model Type 
(cycle length, 
time horizon) 
Model States / 
Tree Summary 
Outcome 
Measures 
Sensitivity 
Analysis 
Result 
Kerstein 
et al. 
2001 [33] 
CEA 
Hydrocolloid 
Dressing 
(DuoDERM) 
Apligraf, Saline 
Gauze 
USA, Not 
stated 
USD ($) 
2000 
Not Detailed Not Detailed 
Proportion of 
ulcers 
completely 
healed 
None 
Intervention 
Dominant 
Sibbald et 
al. 2001 
[40] 
CEA 
Skin 
substitute 
(Apligraf) 
Profore 
Canada, 
Societal 
Canadian 
dollars ($) 
1996/97 
Not Detailed - 
"Computer-
based model" 
Not Detailed 
Number of 
ulcer days 
Days to heal 
Univariate 
Deterministic 
$14 per 
ulcer day 
averted 
Meaume 
et al. 
2002 [26] 
CEA 
Hydrocolloid 
Dressing 
(DuoDERM) 
Apligraf 
France, 
Health 
Insurance 
Plan 
Euros (€) 
Not stated 
Not Detailed Not Detailed 
% patients 
healed 
None 
Intervention 
Dominant 
Panca et 
al. 2013 
[25] 
CUA 
Sodium 
carboxymeth
yl-cellulose 
dressing 
(Aquacel) 
Four 
superabsorbent 
dressings 
(DryMax Extra, 
Flivasorb, 
Kerramax, 
sachet S) 
UK, NHS 
GBP (£) 
2003/04 
Not Detailed - 
"Decision 
Model" 
Not Detailed QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
Guest et 
al. 2017 
[37] 
CEA 
+ 
CUA 
Two-layer 
cohesive 
compression 
bandage 
(Coban 2) 
Other 
compression 
systems (Ktwo, 
Profore) 
UK, NHS 
GBP (£) 
2014/15 
Not Detailed Not Detailed 
% of Healed 
Patients 
QALYs 
Univariate 
Deterministic, 
Probabilistic 
Intervention 
Dominant 
CEA = Cost-Effectiveness analysis, CUA = Cost-Utility Analysis, EE = Economic Evaluation, QALY = Quality adjusted life years, GBP = British Pound, USD = United States 
Dollar 
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3.2. Quality Assessment 
The reporting and methodological quality of studies was evaluated using the Philips Checklist [20]. 
The responses given for each study are included in the Electronic Supplementary Material (Appendix 
3). To allow for analysis of these results, a measurement system calculated the percentage of criteria 
fulfilled. A yes, ‘Y’ response counted as one point, a no ‘N’ response as no points, a partial ‘P’ 
response as half of a point, and criteria given a ‘N/A’ response were discounted from calculation. 
Although this scoring system could be criticised for assuming equal weighting to all criteria, it allows 
for an estimate of number of items fulfilled. The scores from this ranged from 27% up to 89%, with the 
scores for included studies found in the Electronic Supplementary Material (Appendix 3). 
The following discussion of study quality follows the three domains of the Philips Checklist, ‘model 
structure’, ‘data’ and ‘uncertainty and consistency’. 
3.2.1. Model Structure 
Selecting an appropriate model structure is key for decision-analytic models. Appropriate models 
should best reflect the disease process, relevant healthcare system and available evidence for the 
decision problem [47]. 
In the majority of studies, relatively little explanation was given for the selection of the type and 
structure of decision-analytical model. Only two studies (9%) gave full evidence as to how the model 
structure was formed [38, 39], whilst other possible model structures were considered by only one 
study [39]. Model structures should align with the biological and clinical theory of the condition 
studied, and should be driven by the study question rather than data availability [20, 48]. By not 
detailing the rationale for the model structure used, it cannot be determined whether the model was 
the best fit for the study objective, or whether it was chosen due to data limitations. This reduces the 
perceived quality of the study.  
The Markov models used in the included studies often had a simplistic structure. Commonly, the 
following states were used, ‘healed’, ‘unhealed’ and ‘dead’ [38, 41, 46], whilst some studies included  
more detailed states such as ‘improved’, ‘worsened’ and ‘complications’ [24, 44]. The cycle lengths 
used in the Markov models ranged from one day to one month, with this length mostly determined by 
the frequency of outpatient appointments. This is despite it being recommended that cycle length is 
based on the natural history of disease and not local treatment patterns [49]. 
13 studies (57%) were considered to have a time horizon that was insufficient to reflect important 
differences between the options [25-27, 29, 30, 32, 33, 36, 37, 40, 43-45]. Although most VLUs are 
cured within three to four months, treatment can go on to take much longer [2]. The time horizon was 
often determined from available trial data [28, 29, 39, 42-44], with no attempts to extrapolate this data 
to a more suitable economic time horizon being made. Guidelines suggest that a lifetime horizon is 
considered optimal for all decision-analytic models to ensure that no associated costs or benefits are 
missed [13, 50]. No study used a lifetime horizon within this systematic review and only four papers 
(17%) fully justified using a shorter time horizon [28, 29, 38, 46]. 
Only two papers (9%) adopted a societal perspective [29, 40]. Societal perspectives are 
recommended, as narrower perspectives may lead to important costs and benefits being ignored [13, 
50, 51]. Of these two studies, Scanlon et al did not include any indirect costs despite reporting to use 
a societal perspective, reasoning that “due to the relatively high average age of people with venous 
leg ulcers, no costs of lost workdays were applied” [29]. Whilst Sibbald et al, included loss of work as 
the only indirect cost considered [40], excluding other potential indirect costs, such as patient 
transport or time lost from daily activities. This review found an absence of a true societal perspective 
when evaluating the cost-effectiveness of VLU treatments.  
Half-cycle corrections were not used by any papers using a Markov model within this review. 
Reasoning for their exclusion was only given by Nherera et al, who stated “for the study model, the 
cycle length was considered to be small enough not to require a half-cycle correction” [34]. Whilst 
half-cycle correction is a criteria on the Philips Checklist, the need for such a correction is contested 
[52, 53]. 
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3.2.2. Data 
An important strength of model-based economic evaluations in comparison to trial-based evaluations 
is that they allow authors to source all relevant evidence to help answer the study objective [13, 50]. 
Despite this, only nine (39%) of the studies used systematic literature reviews to inform model 
parameters [24, 26, 29, 30, 32-34, 38, 41]. The details of what these reviews involved and the results 
from them were embedded within the studies, with no literature reviews published separately. The 
remaining studies used single sources of data, with nine models using randomised controlled trials for 
data inputs [28, 31, 35, 39, 40, 42-44, 46] and five using The Health Improvement Network (THIN) 
database [25, 27, 36, 37, 45]. There is potential when using only a single source of data that the 
generalisability of the results is reduced.  
Expert panels were used in 12 (52%) of the studies [26, 29, 30, 32-34, 37, 39-42, 44]. These panels 
mostly consisted of health care professionals, whose estimations were used to compensate for gaps 
in research data. Whilst the use of expert opinion is acceptable, it was adjudged by Coyle and Lee to 
be at the bottom of the hierarchy for data sources [54], and should only be used as a last resort when 
no other data can be obtained [55]. Two studies did not detail the methods used in eliciting expert 
opinion or who the experts were [34, 41]. 
3.2.3. Uncertainty and Consistency 
Using decision-analytic models in economic evaluations allows authors to assess and analyse the 
uncertainty associated with decision making [13, 49, 50]. The Philips Checklist divides uncertainty into 
four dimensions: methodological, model structure, heterogeneity and parameter uncertainty. 
Uncertainty regarding methodology, model structure and heterogeneity were poorly assessed by the 
studies included in the review. Methodological uncertainties were evaluated by only 5 studies (22%) 
[29, 35, 38, 42, 46]. These studies ran their sensitivity analyses with different weighting of data used 
[46], different time horizons [29] and with different clinical scenarios [35]. Structural uncertainties were 
not addressed by any studies in the review. Heterogeneity was assessed by only two studies (9%), 
which examined populations from a different country [30] and with a different type of VLU [27]. 
Parameter was the most commonly addressed dimension of uncertainty, which was completed by 16 
studies (70%) [25, 27, 29-31, 34, 36-39, 41-46]. Sensitivity analyses were run on parameter estimates 
including resource use, unit costs and clinical outcomes. It is suggested that parameter uncertainty 
should be tested using probabilistic analysis [20], which was performed by six out of the 16 papers 
(38%) [27, 30, 34, 38, 41, 46]. The majority of studies instead conducted univariate deterministic 
analysis [25, 27, 29, 30, 36, 37, 39, 42, 44, 45]. Univariate analysis allows for the impact of individual 
parameters to be assessed but is not recommended for testing uncertainty and should instead be 
used in the model development process [50]. It is also recommended that when testing uncertainty, 
the range of values for a parameter should be well justified [20], however many models used arbitrary 
percentage variation without reasoning (e.g. +/- 20% base case) in their sensitivity analysis [25, 27, 
29, 30, 36, 37, 39, 42-45].  
There were some flaws in how the results of the modelling studies were presented. Kerstein et al [33] 
and Meaume et al [26] reported an average cost-effectiveness ratio (ACER) rather than an 
incremental cost-effectiveness ratio (ICER), which are considered as the standard summary 
measures of economic evaluations [7, 50]. ACERs should not be used to report the results of 
analyses, as they assume that all outcomes are produced at equivalent cost and spread additional 
costs from an intervention over all previous outcomes, which is not the case [56, 57]. Negative ICERs 
were reported by Walzer et al [24], despite describing the intervention (Sachet S) as dominant. It is 
unconventional to report negative ICERs, given that presented without context, they do not show if an 
intervention offers a decreased cost for an increased benefit or an increased cost for a decreased 
benefit [50]. 
The 2012 study by Guest et al [45] stated that cost-effectiveness would be determined by the clinical 
outcomes of QALY gain and percentage of healed patients. However, after the results from the study 
showed that there were no differences in costs or clinical outcomes for all interventions, the study 
then reported on a previously unmentioned outcome (wound size reduction) as the reasoning behind 
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recommending one of the interventions as the preferred strategy. Using post-hoc outcome measures 
has the potential for bias, given that they may be selected on the basis of clinical or statistical 
significance of the observed results. The validity of this model is therefore reduced, with the potential 
to mislead decision makers.  
4. Discussion 
This systematic review has shown several common themes in published decision-analytic models for 
VLU treatment. The most common model types were Markov models, with new dressing technologies 
the most common intervention investigated. The majority of studies were funded by the health 
technology companies whose product was being evaluated, and were found to be the dominant 
treatment strategy. 
The major themes when critically appraising the reporting and methodological quality of the decision-
analytic models were the limited data sources and the limited length of time horizons over which 
interventions were evaluated. The most significant finding from this review was the large number of 
papers which reported little or no details of the modelling techniques or structure used for the study 
[25, 26, 32, 33, 37, 40]. The lack of reporting detail may impact on how usable the results of these 
studies are. Although it should be noted that these criticisms are not unique to VLU based decision-
analytic models. A systematic review of all decision models in UK health technology assessments, by 
Cooper et al in 2005, found that only 10% of studies across all disease areas suitably reported the 
process involved in developing the model structure [55]. 
This review is believed to be the first to focus on decision-analytic models for VLU treatment but has 
found similar results to other systematic reviews in the domain of wounds. A 2018 review, by Cheng 
et al, reviewed all types of economic evaluations for chronic wounds [58]. The 12 decision-analytic 
models appraised in the Cheng review had similar methodological quality issues as the models 
included in this review, with short time horizons and few studies conducting analyses from a societal 
perspective. The researchers in this paper also criticised the absence of model validation, and models 
using single trials as their data source [58]. There were no decision-analytic models relating to VLU 
treatment in this study, meaning that none of the models evaluated in this review had been previously 
appraised by Cheng et al. Similar methodological shortcomings were commented on in a systematic 
review by Langer and Rogowski in 2009 [59]. This review focused on human-cell derived wound care 
products for both VLUs and diabetic foot ulcers, and found that some of the models included had 
unsuitably short time horizons, used deterministic rather than probabilistic sensitivity analysis and 
methodological issues with ICER calculations and reporting [59]. 
There are several limitations of this review, which may have affected the results. The study selection 
only included published articles available in full text in English, meaning potentially relevant studies 
would have been omitted. The use of the Philips checklist also has limitations. For example, the 
authors of the Philips checklist acknowledge that the framework cannot guide appraisal on the 
suitability of individual model structure and structural assumptions themselves [20]. As well, many of 
the questions in the checklist require subjective interpretation, and whilst the error resulting from this 
would have been minimised by the use of two researchers, this may still be implicit within the results. 
Furthermore, the Philips Checklist was published in 2004, after a number of studies analysed in this 
review [26, 32, 33, 40, 42]. It may therefore be deemed inappropriate or unfair to judge such studies 
on criteria that were formed after their publication, given how modelling techniques and standards are 
likely to have changed over time. Word limitations in journals may also limit the detail authors can 
include in their studies regarding model structure. This should not be an issue for more modern 
papers however, due to the increased likelihood of supplementary materials, but older papers may 
have been restricted when describing the methodology of their studies. 
This review strengthens the calls of previous reviews for future decision-analytic models to improve 
their reporting quality [58, 59]. Despite systematic evidence by Cooper et al showing that model-
based evaluations are not being sufficiently described in studies regardless of disease area, reporting 
thoroughness does not appear to be improving with time [55], a finding echoed within this review. 
Future decision-analytic modelling studies should make use of the increasing ability to include 
supplementary online materials, as well as other transparency initiatives, such as sharing of model 
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code, to greater facilitate reporting clarity. There is also value in publishing the results of any 
systematic literature reviews conducted to identify the baseline data for modelling studies. This review 
highlighted eight studies, that performed their own systematic reviews to identify baseline data inputs 
[24, 26, 29, 30, 32, 33, 38, 41], with Nherera et al the only paper to utilise a previously published 
review [34]. Since none of these studies published the methodology or results of their reviews 
separately, this may have resulted in a duplication of researcher effort, which could have been 
focused on other areas of the modelling process, such as model validation. There is also potential for 
future research to develop guidelines specifically for VLU based models, similar to guidelines 
developed by the Mt Hood Diabetes Challenge Network [60]. A similar review focusing on trial-based 
economic evaluations for VLU treatments would also be of worth, as there is still a significant gap in 
the literature for this area. The review by Cheng et al covered only three trial-based evaluations for 
VLUs [58], finding all three of these to be cost-saving, whilst a review by Weller et al only focused on 
one treatment option (compression therapy), finding five relevant, within-trial, studies [61]. 
5. Conclusion 
Venous leg ulcers are an ever-increasing burden on the health of the ageing population and on the 
budget of healthcare providers. This review has shown that there is a sizeable number of decision-
analytic model-based economic evaluations available to decision makers, but with a large variance of 
methodological quality across the studies. Common issues related to improper evidence for model 
structure, inadequate time horizons and limited data sources. These limitations in study methodology 
provide inferior quality evidence for decision makers to evaluate the cost-effectiveness of potential 
interventions. By acknowledging and avoiding the shortcomings of the evaluations included within this 
review, future work should be of a higher reporting quality, thus providing better quality evidence to 
inform the cost-effectiveness of different venous leg ulcer interventions. 
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